Germany Archives

News and Trends 16 Oct 2014

A Smart Collaboration to Diagnostic and Fight Cancer

New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris. Under this agreement, New Oncology (Cologne-based German Biotech company) will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows rapid sample processing compatible with both […]

October 16, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 15 Oct 2014

Recently Launched Company Rigontec already Raised 9,45M Euros against Cancer

Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced the first closing of its Series A financing round, raising €9.45 million. Rigontec was launched in January 2014 as a spin-out of the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn, Germany. The Company’s […]

October 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 11 Oct 2014

ARTES Biotechnology, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary applications. Nowadays virus-like particles (VLPs) have become a widely used vehicle for the development of vaccines used in humans. Without being infectious, the particles are used to transport foreign antigens in an ideal way to the immune system. For veterinary applications, the applied VLP production […]

October 11, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 8 Oct 2014

Baden-Württemberg Healthcare Industry Forum 2014, discover one of the largest cluster in Germany

Last September 24th was held the Baden-Württemberg Healthcare Industry Forum 2014, organized by BIOPRO the biotech cluster of this German region. It was an opportunity to review the bilan of the cluster and to learn interesting facts. BIOPRO has listed 159 biotech companies in the Baden-Württemberg area, representing a workforce of more than 22,000 employees and a turnover […]

October 8, 2014 - 6 minutesmins - By Joachim Eeckhout

LoneStar Heart Hydrogel advanced heart attacks

News and Trends 4 Oct 2014

A Hydrogel to treat Advanced Heart Failure in Europe

LoneStar Heart, Inc. announced that it received the CE Mark (European Conformity) for its Algisyl-LVR® hydrogel implant,a product for the treatment of advanced heart failure (HF). The CE Mark indicates a product’s compliance with European Union legislation and that it can be sold throughout the European Economic Area. Classified in Europe and in the U.S. as a medical device, Algisyl-LVR is […]

October 4, 2014 - 2 minutesmins - By Julie Lellouche

csm ganymed start bilder04 new 7ec1db04d4

News and Trends 2 Oct 2014

BioNTech and Ganymed Pharmaceuticals Open One of the Largest Research Facilities in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two leading German biotechnology companies, announced today the joint- opening of a new headquarters and research facility of approximatively 10,000 square-meters. The new facility brings together 300 employees and is located close to academic institutions (Johannes-Gutenberg University), hospitals (University Medical Center) and cancer research institutions such as the leading translational oncology […]

October 2, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 22 Sep 2014

Is a new revolution in lung cancer drug treatment coming ?

A new revolutionary treatment could help cure lung cancer. It is based on mRNA instead of antibodies and chemotherapy. Instead of delivering the protein or the drug, only a message is delivering and the body will produce the therapeutics. Curevac, the historic and one of the leading Biotech company in this field announced a 465 million […]

September 22, 2014 - 3 minutesmins - By Philip Hemme

Eli Lilly and Boehringer Ingelheim’s product the first insulin biosimilar approved in Europe2

News and Trends 16 Sep 2014

The first insulin biosimilar has been approved in Europe

The European Commission granted marketing authorisation to Eli Lilly and Company and Boehringer Ingelheim for the first insulin biosimilar glargine product. It is indicated to treat diabetes in adults, adolescents and children aged 2 years and above. The collaboration between the two companies is bearing fruit, it is the first-ever version of this class. It received […]

September 16, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Sep 2014

Affimed secures almost $30M in Financing to continue its clinical development

Affimed Therapeutics today announced that it has closed a $15.7 million (€11.7 million) Series E equity funding led by Affimed’s current investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed. In addition, the Company has signed a $14 million (€10.5 million) loan agreement with Perceptive Advisors, leading to a total of […]

September 3, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 25 Aug 2014

When swimming supports science: Scienion contributes to the “Rheines Wasser” project with micro-array testing

Scienion today announced that the company supports the unique research project ‘Rheines Wasser’ involving a 1,231 km long Rhine marathon swim. SCIENIONs contribution includes water quality testing with a novel multi-parameter microarray, financing all microarrays, sample preparation, experimental work and providing equipment. In the ambitious project ‘Rheines Wasser’, Andreas Fath, a Furtwangen University professor of […]

August 25, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Aug 2014

uniQure acquires the gene therapy start-up InoCard

uniQure, a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease […]

August 20, 2014 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us